Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended that Keytruda's coming loss of ...
Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback